AbbVie Inc. (ABBV) vs BRISTOL MYERS SQUIBB CO (BMY)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | ABBV | BMY |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $61.16B | $48.19B |
| Revenue growth (YoY) | ▲ 8.6% | ▼ 0.2% |
| Net income | $4.23B | $7.05B |
| Gross margin | 70.2% | 71.1% |
| Diluted EPS | $2.36 | $3.46 |
| Insider net (6 mo) | +0 sh • 1 sells • 0 buys | +54.4K sh • 3 sells • 0 buys |
| Institutional owners | 65 | 64 |
| Institutional value held | $229.38B | $65.66B |
| Next earnings (est.) | Around Feb 3, 2027 | Feb 4, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About AbbVie Inc. (ABBV)
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company that develops, manufactures, commercializes and sells advanced therapies for some of the world's most complex and serious diseases. Read more →
About BRISTOL MYERS SQUIBB CO (BMY)
Bristol-Myers Squibb Company (BMS) is a global biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes and sells innovative medicines for patients with serious diseases. Read more →
Source: SEC EDGAR.